ICON in Latin America


Local expertise and site relationship to drive your global project enrolment target with quality and on budget.

ICON has operations in the region since 1998, and has offices in the 6 main countries: Argentina, Brazil, Chile, Colombia, Mexico and Peru, ICON is a leading CRO in the region.

A team of over 570 professionals, with in-depth experience and local expertise, will provide insight on what is required to contribute to global and regional study delivery.

Full range of services

We have a full range of services in Latin America working in teams that are fully integrated regionally and globally:

  • Site & Patient Recruitment
  • Clinical Research Services including:
    •   Study Start-up and logistics
    •   Trial Management and Monitoring
    •   Scientific Operations including Regulatory, Pharmacovigilance and Medical Affairs
  • Commercialisation & Outcomes
  • Medical Device
  • Biosimilars Research
  • Strategic Resourcing Solutions and FSP Services
  • Quality Assurance

ICON: Your Partner in Latin America

ICON has broad experience in the implementation of clinical trials in Latin America.  We were  the first CRO in the region and still one of the largest. This experience enables us to understand and comply with local regulations, customs, and language differences and to efficiently work with the culture and the medical practices in each country of the region– ensuring superior trial compliance and expeditious patient enrolment.

It also enables us to provide sound advice to our clients on how to prevent difficulties and delays in the implementation and development of the trials.

Why Latin America?

Several factors contribute to Latin America being a region of choice to conduct your clinical trials:

Patient Access

  • Over 600 million inhabitants and 80% urban population. Large metropolitan areas provide patient concentrations for stronger enrollment
  • Cardiovascular, arthritis, cancer, and infectious diseases are as prevalent as in the United States.
  • Patient compliance and retention - drop-out rates in the region are one-third those of  US and EU
  • Strong patient-doctor relationship built upon the health infrastructure of each country.
  • Less competition for patients with fewer clinical trials enrolling compared  to US & EU yields superior enrolment rates

Lack of language barrier
Only 2 languages -  Spanish and Portuguese

Quality
Over the last 10 years all FDA site inspections conducted on trials with positive results

Market potential: Substantial market for later sale of approved drugs, with registration accelerated by participation in multi-regional clinical trials. 

We welcome the opportunity to discuss your unique clinical research requirements.